Metabolomics as a Leading Technology in Biomarker Discovery | May 2018
Metabolomics is a powerful tool and has emerged as a leading technology for biomarker discovery to facilitate early diagnosis of disease, prediction of disease progression, monitoring/predicting patient responses to medicines, identification of new drug targets and toxicity profiles. Metabolites are sensitive indicators of homeostatic changes and are tightly coupled to the phenotype, making them excellent candidates for biomarkers. Metabolites also play a crucial role in the signaling and regulation of genes, proteins and microbiota, making metabolomics an ideal complement for other forms of -omics research.
In this webinar, we will focus on an accomplished leader in the field of metabolomics, with analytical capabilities ranging from broad to targeted, and describe how metabolomics is applicable across diverse areas of research in discovery biology, pharmaceutical R&D, clinical trials, nutrition, bioprocessing and cell culture science.
- Gain knowledge/comfortability/confidence in metabolomics technology
- Brainstorm how metabolomics can help to achieve your research goals
- Learn about leading metabolomics technology from global/untargeted to fully quantitative
- Obtain an overview and examples of how metabolomics can accelerate biomarker discovery
About Brian Keppler
Dr. Keppler received his PhD in pharmaceutical sciences from the University of North Carolina at Chapel Hill where he focused on identifying novel ways to inhibit telomerase as an anti-cancer approach. He completed his postdoctoral training at the National Institute of Environmental Health Sciences in the Laboratory of Molecular Carcinogenesis by helping to further elucidate the roles of chromatin remodeling complexes in steroid receptor-mediated gene expression. With an extensive background in a variety of scientific disciplines, Dr. Keppler joined Metabolon in 2011 and works with the company's global pharmaceutical and biotechnology clients.